Liminal BioSciences Inc. (https://liminalbiosciences.com) is a global biotechnology company that specialises in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. We focus specifically on developing solutions for rare and orphan diseases. Liminal BioSciences operates on an integrated basis from our three talent hubs in Laval, Quebec, Canada, Cambridge, UK and Rockville, Maryland, USA. Our common shares are listed for trading on the Toronto Stock Exchange (Symbol:LMNL).



Contact Information
Liminal BioSciences Inc.
[email protected]
+1.450.781.0115 

Latest

Jul 21, 2022, 17:27 ET Liminal BioSciences Announces Discontinuation of Fezagepras Development

LAVAL, QC and CAMBRIDGE, England, July 21, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of...

Jun 06, 2022, 16:05 ET Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England, June 6, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General...

May 23, 2022, 08:00 ET Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 23, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the...

May 10, 2022, 16:30 ET Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple...

May 09, 2022, 16:05 ET Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022

LAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022...

May 09, 2022, 08:30 ET Liminal Biosciences to Present at Upcoming Investor Conferences

LAVAL, QC, and CAMBRIDGE, England, May 9, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that...

Mar 17, 2022, 18:48 ET Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured...

Mar 14, 2022, 08:00 ET Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose...

Mar 07, 2022, 16:59 ET Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

LAVAL, QC, and CAMBRIDGE, ENGLAND, March 7, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written ...

Feb 16, 2022, 07:15 ET Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP

Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its...

Jan 19, 2022, 16:05 ET Liminal BioSciences Announces Strategic Priorities For 2022

LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate...

Nov 15, 2021, 17:15 ET Liminal BioSciences Reports Third Quarter 2021 Financial Results

Closing of the Sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A...

Oct 15, 2021, 16:54 ET Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the...

Sep 28, 2021, 16:10 ET Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /CNW/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics ...

Aug 16, 2021, 16:05 ET Liminal BioSciences Reports Second Quarter 2021 Financial Results

Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to...

Aug 09, 2021, 07:30 ET Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics ...

Jul 09, 2021, 16:00 ET Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today...

Jun 23, 2021, 08:30 ET Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion

LAVAL, QC and CAMBRIDGE, England, June 23, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has...

Jun 04, 2021, 16:27 ET Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and ...

Jun 04, 2021, 15:30 ET Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration ...

May 28, 2021, 16:30 ET Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 28, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced...

May 21, 2021, 16:45 ET Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

LAVAL, QC and CAMBRIDGE, England, May 21, 2021 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced...

May 17, 2021, 16:30 ET Liminal BioSciences Reports First Quarter 2021 Financial Results

Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived...

May 17, 2021, 08:30 ET Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net...

Mar 24, 2021, 16:39 ET Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results

Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a ...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE